{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T07:10:10Z","timestamp":1778310610222,"version":"3.51.4"},"reference-count":22,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cancer Control"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>This single-center retrospective study aimed to assess the efficacy and safety of first-line rituximab-containing regimens in treatment-na\u00efve patients with mantle cell lymphoma (MCL) in a resource-constrained setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We included 73 patients diagnosed with MCL between May 2019 and June 2024 who received rituximab-based chemotherapy (RB, RBAC, RDHAP, or RCHOP) at the Vietnam National Cancer Hospital. Clinical characteristics, treatment responses, survival outcomes, and prognostic factors were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median age was 60 years, and the male-to-female ratio was 2.17. Stage IV disease was present in 47.9% of patients and stage III in 38.4%. B symptoms were observed in 27.4%, and Ki-67 &gt;30% in 45.2% of patients. The overall response rate (ORR) was 94.5%, including a complete response rate of 64.4%. The most common grade 3\/4 adverse event was neutropenia (17.8%). The 3-year progression-free survival (PFS) and overall survival (OS) rates were 72.6% and 93.2%, respectively. Mantle Cell Lymphoma International Prognostic Index (MIPI) risk classification, treatment response, and extranodal involvement were associated with PFS, whereas OS was primarily influenced by treatment response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Rituximab-based chemotherapy appears to provide favorable efficacy and manageable toxicity in Vietnamese patients with MCL. These findings suggest that such regimens may remain a feasible first-line option in settings with limited access to novel agents and advanced supportive care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10732748261448964","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T11:53:46Z","timestamp":1778068426000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Outcomes of Mantle Cell Lymphoma Treated With Rituximab-Based Chemotherapy Regimens: Experience From a Single Institution in Vietnam"],"prefix":"10.1177","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6059-7046","authenticated-orcid":false,"given":"Hung Kien","family":"Do","sequence":"first","affiliation":[{"name":"Vietnam National Cancer Hospital - K Hospital"},{"name":"Vietnam National Cancer Hospital - K Hospital"},{"name":"Hanoi Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6830-7339","authenticated-orcid":false,"given":"Nga Huyen","family":"Do","sequence":"additional","affiliation":[{"name":"Vietnam National Cancer Hospital - K Hospital"},{"name":"Hanoi Medical University"},{"name":"Vietnam National Cancer Hospital - K Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1363-8161","authenticated-orcid":false,"given":"Van Tai","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Vietnam National Cancer Hospital - K Hospital"},{"name":"Vietnam National Cancer Hospital - K Hospital"},{"name":"Hanoi Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5271-9738","authenticated-orcid":false,"given":"Tung Thanh","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Vietnam National Cancer Hospital - K Hospital"},{"name":"Hanoi Medical University"},{"name":"Vietnam National Cancer Hospital - K Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binh Duc","family":"Vu","sequence":"additional","affiliation":[{"name":"Hanoi Medical University"},{"name":"Department of Clinical Hematology, National Institute of Hematology and Blood Transfusion"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"e_1_3_6_2_2","first-page":"1","volume-title":"Mantle cell lymphoma: Epidemiology, pathobiology, clinical manifestations, diagnosis, and prognosis","author":"Freedman AS","year":"2024","unstructured":"Freedman AS. Mantle cell lymphoma: Epidemiology, pathobiology, clinical manifestations, diagnosis, and prognosis. Uptodate; 2024:1-25."},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.3390\/hematolrep16010006"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015851"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23608"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023009744"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(97)70212-9"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.3960\/jslrt.25011"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000464"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-369629"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk152"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00739-X"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-348367"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.4103\/sja.SJA_543_18"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2020.100038"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023009744"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01780"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007371"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701769"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02698"},{"key":"e_1_3_6_23_2","first-page":"CD003805","article-title":"Chemotherapy plus Rituximab versus chemotherapy alone for B\u2010cell non\u2010Hodgkin's lymphoma","volume":"4","author":"Schulz H","year":"2007","unstructured":"Schulz H, Bohlius J, Skoetz N, et al. Chemotherapy plus Rituximab versus chemotherapy alone for B\u2010cell non\u2010Hodgkin's lymphoma. Cochrane Database Syst Rev. 2007;4:CD003805.","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Cancer Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10732748261448964","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10732748261448964","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10732748261448964","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T06:18:21Z","timestamp":1778307501000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10732748261448964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":22,"alternative-id":["10.1177\/10732748261448964"],"URL":"https:\/\/doi.org\/10.1177\/10732748261448964","relation":{"has-review":[{"id-type":"doi","id":"10.1177\/10732748261448964\/v3\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748261448964\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748261448964\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748261448964\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748261448964\/v3\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748261448964\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748261448964\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748261448964\/v3\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748261448964\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748261448964\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748261448964\/v1\/review3","asserted-by":"object"}]},"ISSN":["1073-2748","1526-2359"],"issn-type":[{"value":"1073-2748","type":"print"},{"value":"1526-2359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"article-number":"10732748261448964"}}